Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Astellas, the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended September 30, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com.  The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Your Contact at Bayer:Doreen Schroeder, Tel. +49 30 468-11399E-Mail: doreen.schroeder@bayer.com Your Investor Relations Contact at Regeneron:Michael Aberman, M.D. Tel. +1 (914) 345-7799E-Mail: michael.aberma
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)...  UBM Medica US announces that Cancer ... presents exclusive slide shows dealing with communication in the ... care. Cancer Network, the online ... blogs, and podcasts about the latest clinical findings. Among ... , End-of-life care is challenging for even the ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Swiss Exchange: CRX) today announced that following the end of ... Johnson & Johnson has acquired 98.89% of the issued Shares ... Crucell) and 98.93% of the issued and outstanding Shares in ...
... Cellceutix Corporation (Pink Sheets: CTIX ) today ... Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with ... Cellceutix CEO, Leo Ehrlich, commented, "It,s relatively uncommon ... a compound before clinical trials are underway.  The process ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... Alexandria, VA (PRWEB) July 31, 2014 ... Hilton hotel in Chicago, Illinois, the Mesothelioma Applied ... Chicago Medicine, will host a one-day regional ... members, covering a variety of topics related to ... , Some of the covered topics will include ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Leelanau Peninsula’s newest ... July 3, 2014 at 7788 East Horn Road in Lake ... Wine Trail , Aurora Cellars is the 25th winery along ... including the popular wine tour events, making its trail event ... 6-7, 2014. , Owners David and Faye Mathia opened ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... Memphis, TN (PRWEB) July 31, 2014 In ... are required for proper storage of necessary life saving ... and staff. Unfortunately there is still a high number of ... is an EMT who steals the narcotics and even replaces ... urgent relief receives none. As seen in the case in ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:United Theological Seminary to Open 144th Year 2Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2
... inheritable genes to enable people to produce more ‘perfect’ ... and on being human, warns a leading US science ... out great hope for IGM technology, which offers them ... Disease and schizophrenia on to their children.// ,However, ...
... the risk of pancreatic cancer in both sexes,while moderate ... obese individuals,says Dr. Dominique S. Michaud the head ... National Cancer Institute in Rockville, Maryland and colleagues collected ... 75 years of age, who participated in the Health ...
... popular belief, the heart can actually repair itself by growing new ... researchers in New York and Italy. Dr. Piero Anversa and colleagues ... heart muscle cells called myocytes continued to divide after a heart ... examined the hearts of 13 people who died within a few ...
... patients suffering from Angina may have some new treatment ... Angina, a common cardiovascular disorder affecting millions of people ... by blood vessels too clogged to get oxygen-rich blood ... either medication or for more serious cases, rerouting the ...
... piglets last week could significantly increase the success rate ... research has indicated that rejection of animal cells and ... to the presence of the gene alpha 1,3 galactosyl ... a sugar// to the surface of pig cells, flagging ...
... A new technique to keeping heart arteries flowing easily ... solving a major weakness of the common procedure.Doctors ... - the drug-coated stent. In testing on 30 patients ... percent effective, an accomplishment almost unheard of in medicine.// ...
Cached Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... a non-invasive and painless method of stimulating ... Laboratories manufactures two magnetic stimulation devices, the ... (HSMS). The Hight Speed MES-10 ... up to 25 Hz at full power. ...
... MOBEE headboxes are the ... line of portable battery-powered ... a robust new mechanical ... software, XLTEK's standard MOBEE24plus ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: